- Home
- CHNR vs MIRA Comparison
CHNR vs MIRA Comparison
Compare CHNR & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- MIRA
- Stock Information
- Founded
- CHNR N/A
- MIRA 2020
- Country
- CHNR China
- MIRA United States
- Employees
- CHNR N/A
- MIRA N/A
- Industry
- CHNR Precious Metals
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- CHNR Basic Materials
- MIRA Health Care
- Exchange
- CHNR Nasdaq
- MIRA Nasdaq
- Market Cap
- CHNR 4.6M
- MIRA 19.5M
- IPO Year
- CHNR 1995
- MIRA 2023
- Fundamental
- Price
- CHNR $3.68
- MIRA $1.20
- Analyst Decision
- CHNR
- MIRA Strong Buy
- Analyst Count
- CHNR 0
- MIRA 2
- Target Price
- CHNR N/A
- MIRA $14.00
- AVG Volume (30 Days)
- CHNR 152.8K
- MIRA 1.9M
- Earning Date
- CHNR 05-15-2025
- MIRA 08-12-2025
- Dividend Yield
- CHNR N/A
- MIRA N/A
- EPS Growth
- CHNR N/A
- MIRA N/A
- EPS
- CHNR N/A
- MIRA N/A
- Revenue
- CHNR N/A
- MIRA N/A
- Revenue This Year
- CHNR N/A
- MIRA N/A
- Revenue Next Year
- CHNR N/A
- MIRA N/A
- P/E Ratio
- CHNR N/A
- MIRA N/A
- Revenue Growth
- CHNR N/A
- MIRA N/A
- 52 Week Low
- CHNR $3.57
- MIRA $0.51
- 52 Week High
- CHNR $9.04
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- CHNR 41.21
- MIRA 46.10
- Support Level
- CHNR $3.66
- MIRA $1.21
- Resistance Level
- CHNR $4.07
- MIRA $1.26
- Average True Range (ATR)
- CHNR 0.41
- MIRA 0.09
- MACD
- CHNR -0.04
- MIRA -0.01
- Stochastic Oscillator
- CHNR 8.94
- MIRA 29.63
About CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.